

**Policy: MPA M2068**

**Section: Medical Policy**

**Subject: Testing for Alpha-1 Antitrypsin Deficiency**

### Applicable Lines of Business

<b>Commercial</b>	<b>x</b>	<b>CHIP</b>	<b>x</b>
<b>Medicare</b>	<b>x</b>	<b>ACA</b>	<b>x</b>
<b>Medicaid</b>	<b>x</b>		

### I. Policy: Testing for Alpha-1 Antitrypsin Deficiency

**II. Purpose/Objective:** To provide a policy of coverage regarding

**III. Responsibility:**

- A. Medical Directors
- B. Medical Management

### IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

**Commercial**

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

**Medicare**

Geisinger Gold Medicare Advantage HMO, PPO, and HMO D-SNP plans are offered by Geisinger Health Plan/Geisinger Indemnity Insurance Company, health plans with a Medicare contract. Continued enrollment in Geisinger Gold depends on contract renewal. Geisinger Health Plan/Geisinger Indemnity Insurance Company are part of Geisinger, an integrated health care delivery and coverage organization.

**CHIP**

Geisinger Health Plan Kids (GHP Kids) is a Children’s Health Insurance Program (CHIP) offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

**Medicaid**

Geisinger Health Plan Family (GHP Family) is a Medical Assistance (Medicaid) insurance program offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

### V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

### Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.
- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age.

### Testing for Alpha-1 Antitrypsin Deficiency

Policy Number: AHS – M2068 – Testing for Alpha-1 Antitrypsin Deficiency

Original Effective Date: 06/01/2022  
Current Effective Date: 02/01/2026

[POLICY DESCRIPTION](#) | [RELATED POLICIES](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [TABLE OF TERMINOLOGY](#) | [SCIENTIFIC BACKGROUND](#) | [GUIDELINES AND RECOMMENDATIONS](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

### Policy Description

Alpha 1-antitrypsin deficiency (AATD) is a genetic disease that causes deficient or defective production of the alpha-1 antitrypsin (AAT) protease inhibitor that can affect the lungs, liver, and (rarely) skin.<sup>1</sup> AAT deficiency results in unbalanced rapid breakdown of proteins, especially in the supporting elastic tissue of the lungs.<sup>2</sup>

### Related Policies

Policy Number	Policy Title
N/A	Not Applicable

### Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the "Applicable State and Federal Regulations" section of this policy document.

- 1) For individuals who are suspected of having alpha-1 antitrypsin (AAT) deficiency, serum quantification of alpha-1 antitrypsin (AAT) protein **and** AAT phenotyping **or** AAT proteotyping (see Note 1) **MEETS COVERAGE CRITERIA** once per lifetime in **any** of the following situations:
  - a) For symptomatic individuals 18 years or older with emphysema, COPD, or asthma.

- b) For individuals with unexplained liver disease (e.g., chronic hepatitis with or without cirrhosis, chronically elevated aminotransferase levels, portal hypertension, primary liver cancer).
  - c) For individuals with persistent obstruction on pulmonary function tests without identifiable risk factors (e.g., cigarette smoking, occupational exposure).
  - d) For individuals 18 years or older with necrotizing panniculitis.
  - e) For the siblings of an individual with known alpha-1 antitrypsin (AAT) deficiency.
  - f) For individuals with anti-proteinase three-positive vasculitis (C-ANCA [anti-neutrophil cytoplasmic antibody]-positive vasculitis).
  - g) For individuals with bronchiectasis without evident etiology.
  - h) For individuals with neonatal cholestasis.
- 2) For individuals who have negative genotype results for common variants or who have discordant results between AAT serum levels and proteotype, but for whom a clinical suspicion of AAT deficiency remains, isoelectric focusing/phenotyping **MEETS COVERAGE CRITERIA**.

*The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.*

- 3) For all other situations not described above, testing for AAT deficiency **DOES NOT MEET COVERAGE CRITERIA**.

## NOTES:

**Note 1:** AAT phenotyping should be performed using isoelectric focusing. AAT proteotyping (Pi-typing or protease inhibitor typing) for Z and S alleles should be performed using liquid chromatography-tandem mass spectrometry.

## Table of Terminology

Term	Definition
AIAT	Alpha-1 antitrypsin
AAT	Aspartate aminotransferase
AATD	Alpha 1-antitrypsin deficiency
ACG	American College of Gastroenterology
ALT	Alanine transaminase
AST	Aspartate aminotransferase
ATS/ERS	American Thoracic Society/European Respiratory Society
C-ANCA	C-Anti-neutrophil cytoplasmic antibody
CMS	Centers for Medicare and Medicaid Services
COPD	Chronic obstructive pulmonary disorder
CTS	Canadian Thoracic Society
ERS	European Respiratory Society
GC	Gas chromatography
GOLD	Global Initiative for Chronic Obstructive Lung Disease
HPLC	High-performance liquid chromatography
LBV	Likely benign variants
LDTs	Laboratory developed tests
MALDI	Matrix-assisted laser desorption ionisation
<i>MMP-12</i>	<i>Matrix metalloproteinase-12 gene</i>
MS-TOF	Time of flight mass spectrometry
NAFLD	Non-alcoholic fatty liver disease

NICE	National Institute Health and Care Excellence
NORD	National Organization for Rare Disorders
ON-CD	Ontario Center
PCR	Polymerase chain reaction
Pi	Protease inhibitor
PiMZ	Protease inhibitor Z allele
PV	Pathogenic variant
QTOF	Quadrupole time of flight
RCTs	Randomized controlled trials
RFLP	Restriction fragment length polymorphism
<i>SERPINA1</i>	Serine protease inhibitor
UMV	Undefined molecular variants
WHO	World Health Organization

## Scientific Background

Alpha-1 antitrypsin deficiency (AATD) is an underrecognized genetic condition that affects approximately 1 in 2,000 to 1 in 5,000 individuals and predisposes to liver disease and early-onset emphysema.<sup>3</sup> It is estimated that up to 80,000 to 100,000 people in the United States have the severe form of the disease (homozygous in null or abnormal alleles).<sup>4</sup> There is much variation in the disease prevalence in other nations,<sup>5</sup> but most current estimates are that three million people worldwide have severe AATD.<sup>6</sup>

Alpha-1 antitrypsin deficiency is a result of abnormal alpha-1 antitrypsin (AAT) protein inherited in an autosomal recessive pattern with codominant expression in which both genes inherited can be active and contribute to the genetic trait they control. AAT is a member of the serine protease inhibitor (Pi) family, referred to as “serpins”, and it inhibits the proteolytic enzymes elastase, trypsin, chymotrypsin, and thrombin. AAT is encoded by the gene *SERPINA1*.<sup>6</sup>

The AAT protein is produced in the liver and has a role in protecting lungs from injury by neutrophil elastase, which is secreted by white blood cells as a response to inflammation or infection. If the enzyme remains unchecked by AAT protein, damage to alveoli resulting in chronic obstructive pulmonary disease can occur. This includes emphysema, asthma, bronchiectasis, and spontaneous pneumothorax. Smoking and other environmental exposure can cause further damage.<sup>1,6</sup>

Abnormal molecules of AAT protein caused by this illness can also cause liver dysfunction. Pathologic polymerization of the variant AAT can occur, resulting in intrahepatocyte accumulation of AAT molecules, leading to cirrhosis, fibrosis, cholestasis, or hepatomegaly. Liver disease is more common in individuals with certain allele combinations. Gender and obesity may be risk factors for progression to advanced liver disease in adulthood among patients with severe AAT deficiency. In contrast, alcohol use and viral hepatitis do not appear to increase the risk of progressive hepatic failure.<sup>1</sup> AATD is a common genetic cause of liver disease in children.<sup>7</sup>

Skin manifestations of AATD are also recognized. The most associated skin condition is necrotizing panniculitis. In this condition, inflammatory skin lesions are thought to be a consequence of the AAT protein loss of function and subsequent unchecked proteolysis enzyme activity in the skin and subcutaneous tissue. Associations between alpha-1 antitrypsin (AAT) and vascular disease, inflammatory bowel disease, glomerulonephritis, and vasculitis have been proposed but not definitively established.<sup>1</sup>

Due to the numerous alleles associated with AAT, each allele has been given a letter code based on the “electrophoretic mobility of the protein produced”. The normal allele is the “M” allele, and the most common mutation is the “Z” allele. This system applies for each individual allele; for example, a homozygous Z genotype

would be denoted as “ZZ”. Similarly, a wildtype (or “normal”) genotype would be “MM”. Besides the normal phenotype, the three other categories of AAT include “deficient” in which insufficient AAT is produced; “null” in which no AAT is produced at all; and “dysfunctional” in which a typical amount of AAT is produced, but the AAT protein does not function correctly.<sup>6</sup>

Laboratory testing for AATD is comprised of three strategies: serum or plasma AAT quantification, AAT protein phenotyping, and genotyping. Guidelines from national and international societies (e.g., World Health Organization, Spanish Society of Pneumology and Thoracic Surgery, European Respiratory Society) recommend testing for AATD at least once per lifetime for all individuals with liver disease of unknown etiology and for all individuals with chronic obstructive pulmonary disorder (COPD), emphysema, or adults with asthma and irreversible airflow obstruction.<sup>8</sup>

### ***Proprietary Testing***

Initial testing often begins with serum quantification of AAT protein. This can be done through several methods, including immune turbidimetry and nephelometry.<sup>6</sup> A low level is generally represented by a serum level below 11 micromol/L (less than 57 mg/dl using nephelometry). Due to the variation of reference ranges in different testing methodologies, most labs will complete isoelectric phenotyping on any individual with a serum AAT levels of < 100 mg/dL (18.4 micromol/L). In fact, the American Thoracic Society suggests persons with borderline serum levels (defined as 12-35 micromoles or 90 to 140 mg/dL) have qualitative testing.<sup>9</sup>

Isoelectric immunophenotype testing uses the difference in migration rates of allele variants under isoelectric focusing. For example, the M variant will migrate to the middle of the gel, Z will migrate the slowest, and F migrates quickly to the side closest to the anode. This is not a genetic test. On occasion the results can be inconclusive or discordant with quantitative testing, requiring genotype testing of the most common variants.<sup>6</sup>

Genotype testing for the most common allele variants can be utilized where isoelectric immunophenotype testing is inconclusive. Usually polymerase chain reaction (PCR) or restriction fragment length polymorphism (RFLP) techniques are utilized to determine if the most common alleles are present. When dealing with the possibility of a rare variant or null allele, full gene sequencing can be utilized as a final diagnostic measure.<sup>6</sup>

In 2017, Grifols won FDA approval for AAT Deficiency Test, which is capable of simultaneously analyzing 99% of the most prevalent known mutations causing alpha-1 antitrypsin deficiency. The molecular test analyzes simultaneously 192 samples per kit, and in a single reaction, identifies 14 of the most prevalent known mutations in the *SERPINA1* gene, responsible for this genetic disorder.<sup>10</sup>

Using Progenika’s FDA-cleared A1AT Genotyping Test, Matrix Clinical Labs released the proprietary Alpha ID screening test, a comprehensive targeted genetic test assessing 14 common and rare alleles in the *SERPINA1* gene. The Alpha ID screening test utilizes a noninvasive cheek swab screen. If a positive result is found using this test, a follow-up test, Alpha ID Confirm, uses a finger stick and a blood spot card to assess A1AT protein levels as well a potential reflex to next-generation sequencing (NGS) to help physicians achieve an accurate diagnosis of Alpha-1 antitrypsin deficiency (A1ATD).<sup>11</sup>

### ***Clinical Utility and Validity***

The literature on the analytic and clinical validity of genetic testing for AATD is limited. In addition, few randomized controlled trials (RCTs) have evaluated the impact of AATD testing on patient outcomes. Current evidence-based guidelines for diagnosis and management of AATD recommend specific interventions for patients with emphysema and AATD.<sup>12</sup> AAT augmentation therapy is often prescribed for patients with AATD and COPD. In addition, several studies have documented that the disease is underrecognized with delay in diagnosis of between five to eight years.<sup>13,14</sup>

Snyder, et al. (2006) evaluated the laboratory methods of assessing AATD. Samples from 512 individuals were analyzed, and “A1AT concentrations were measured by nephelometry. Phenotype analysis was performed by

isoelectric focusing electrophoresis. The genotype assay detected the S and Z deficiency alleles by a melting curve analysis.” Of these 512 samples, 10 (2%) were discordant between genotype and phenotype. Of these 10 results, seven were attributed to phenotyping errors. Four percent of the samples submitted to genotype and quantitative analysis were “reflexed” to phenotyping, where phenotyping confirmed the genotype result 85% of the time. The investigators concluded, “The combination of genotyping and quantification, with a reflex to phenotyping, is the optimal strategy for the laboratory evaluation of A1AT deficiency.”<sup>15</sup>

Sorroche, et al. (2015) examined a cohort of COPD patients and the prevalence of severe AATD. A total of 1002 patients were evaluated, and 785 (78.34%) had normal AAT levels. The remaining 217 patients had low AAT levels, but only 15 patients had a genotype associated with severe AATD. Of these 15 patients, 12 were ZZ and three were SZ. Of the 202 other patients, 29 were a Z heterozygote, 25 were an S heterozygote, and four were an SS homozygote. Lastly, 144 patients could not be definitively diagnosed.<sup>16</sup>

Cordeiro, et al. (2011) examined the prevalence of AATD in a supposed “high-risk” area. A total of 817 residents participated, and 67 had low AAT serum levels. Overall, 118 residents carried AATD-related alleles, 114 of which were heterozygotes “(46 Z, 52 S, 9 P(brescia), 4 M(wurzburg), 2 I, 1 P(lowell)”. The authors concluded, “the large number of mostly asymptomatic individuals with AATD identified suggests that in high-risk areas adult population screening programs employing the latest genetic methods are feasible.”<sup>17</sup>

Soriano, et al. (2018) evaluated the prevalence of AATD testing in COPD patients. The patient sample came from “550 UK Optimum Patient Care Research Database general practices”. Out of 107,024 COPD patients, only 2.2% had any record of being tested for AATD. Of those tested, 23.7% were diagnosed with AATD. The investigators also noted that between 1994 and 2013, the incidence of AATD diagnosis increased. The authors concluded “that AATD remains markedly underdiagnosed in COPD patients.”<sup>18</sup>

Greulich, et al. (2016) evaluated the results of a large, targeted screening program for AATD. The samples were distributed by a German AAT laboratory over a period of 12 years, and 18,638 testing kits were obtained. Of this sample, 6919 carried at least one mutation, and 1835 patients were considered to have severe AATD. Overall, 194 of these patients had “rare” genotypes. The authors concluded that “among clinical characteristics, a history of COPD, emphysema, and bronchiectasis were significant predictors for Pi\*ZZ, whereas a history of asthma, cough and phlegm were predictors of not carrying the genotype Pi\*ZZ.”<sup>19</sup>

Mattman, et al. (2020) compared the comprehensiveness and efficiency of pathogenic variant (PV) detection of four different protocols from 2011 to 2018 in laboratories across Canada. From 5399 index patients, 396 ZZ genotypes were identified. The protocol for serum A1AT concentration/DNA sequencing in the Ontario center (ON-CD) yielded the highest PV detection – “genotypes with at least one PV, other than S, Z, or F, were identified at 0.67/ZZ as compared to <0.2/ZZ (all others).” However, it also had the highest rates of undefined molecular variants (UMV) (0.16/ZZ vs <0.12/ZZ) or likely benign variants (LBV) compared to all others (0.08/ZZ vs <0.06/ZZ). The authors concluded the “strategies with readily detect variants across the full coding sequence of *SERPINA1* detect more PV as well as more UMV and LBV.”<sup>20</sup>

Hamesch, et al. (2019) evaluated the clinical landscape of liver symptoms in patients with AATD, specifically the Pi\*ZZ genotype. A total of 554 patients (403 exploratory cohort, 151 confirmatory cohort) were included and were compared to 234 controls without pre-existing liver disease. The authors found significantly higher levels of serum liver enzymes in the Pi\*ZZ carriers compared to controls, further noting that “significant” fibrosis was suspected in 20%-36% of Pi\*ZZ carriers. Signs of advanced fibrosis were 9 to 20 times more common in carriers compared to non-carriers. Controlled attenuation parameter of  $\geq 280$  dB/m, which suggests “severe” steatosis was detected in 39% of carriers compared to 31% of controls. Finally, Pi\*ZZ carriers were found to have lower serum concentrations of triglyceride, low, and very-low density lipoprotein cholesterol compared to controls, which the authors suggested to represent impaired hepatic secretion of lipid. Overall, the authors concluded that they identified evidence of liver steatosis, impaired liver secretion, liver fibrosis, and that their data could assist in hepatologic management of Pi\*ZZ carriers.<sup>21</sup>

Strnad, et al. (2019) investigated the impact of the Pi\*Z and Pi\*S genotypes on subjects with non-alcoholic fatty liver disease (NAFLD) or alcohol misuse. Separate cohorts of 1184 with NAFLD and 2462 with chronic alcohol abuse were included. The authors found Pi\*Z genotypes in 13.8% of patients with cirrhotic NAFLD but only 2.4% of patients without liver fibrosis. From there, the increased risk of NAFLD subjects to develop cirrhosis was found to be 7.3 times higher in Pi\*Z carriers. The Pi\*Z variant was also found in 6.2% of alcohol abusers but only 2.2% of alcohol abusers without significant liver injury. The increased risk was found to be 5.2 times higher in Pi\*Z carriers. The Pi\*S variant was not associated with NAFLD-related cirrhosis and only mildly with alcohol-related cirrhosis (increased risk = 1.47 times). The authors concluded that the Pi\*Z variant was the strongest “single nucleotide polymorphism-based risk factor for cirrhosis in NAFLD and alcohol misuse, whereas the Pi\*S variant confers only a weak risk in alcohol misusers” and remarked that this finding should be considered in future genetic counseling of affected individuals.<sup>22</sup>

Carreto, et al. (2020) examined the utility of routine screening for AATD among patients with bronchiectasis, due to the contradiction in guidelines from the British Thoracic Society, which recommend screening for bronchiectasis among patients with AATD, but not vice versa. After screening 1600 patients with bronchiectasis from two centers in the UK from 2012-2016, they found only eight patients with AATD. They concluded that because of the low prevalence of AATD as an etiology for disease presentation among patients with bronchiectasis, routine screening for AATD would not significantly impact clinical management through augmentation therapy, smoking cessation, and genetic counseling, among other methods. Despite this, the researchers did note that higher rates of detection may be found in other geographical regions in the UK or in other countries.<sup>23</sup>

Murray, et al. (2021) evaluated the efficacy of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) (proteotyping)-based algorithm for AATD detection (n=5474), as compared to the more traditional isoelectric focusing (IEF) phenotyping (n=16147). Here, the authors found that LC-MS/MS reduced the rate of IEF phenotyping by 97% and the 3% of cases that were reflexed to IEF resulted in an additional 0.2% of phenotype findings. By retrospectively applying the proteotype-based algorithm to the IEF cohort, they demonstrated a 99.9% sensitivity for the detection of deficiency-associated phenotypes. The authors concluded that the “proteotype algorithm is a sensitive and cost-effective approach for the diagnosis of clinical AAT deficiency.”<sup>24</sup>

Bellemare, et al. (2021) studied the clinical utility of determining the allelic background of mutations causing alpha-1 antitrypsin deficiency. *SERPINA1* was DNA sequenced to identify rare variants that could confer the risk of developing emphysema. Seven carriers of a rare variant, Leu353Phe\_fsTer24, known to lead to undetectable serum levels of AAT, were studied using an allele-specific DNA sequencing method that they developed. Results demonstrated that Leu353Phe\_fsTer24 variant was transmitted on the same allele as the M3 variant in all the patients and two of the seven patients had either a S or Z allele. The lowest AAT serum levels were observed in compound heterozygotes for the S or Z allele, suggesting higher risk of developing emphysema. This study showed that understanding the clinical significance of genetic variants found in *SERPINA1* can lead to better clinical outcomes.<sup>25</sup>

Ashenhurst, et al. (2022) conducted a study to examine whether direct-to-consumer genetic testing increased the identification of previously undetected individuals specifically with AATD, and whether it impacted clinical care. In this cross-sectional study using a survey from the 23andMe, Inc. research platform with 195,014 participants, researchers found that the allele frequency of PI\*S was 15.1%, 6.5% for PI\*Z, and 0.63% with PI\*ZZ. Half of those with the PI\*ZZ allele combination were able to confirm their diagnosis with a physician. Twenty seven percent of the participants were first made aware of their disease status through this test, and among these participants, “the diagnostic delay interval was 22.3 years.” As a result of this finding, there was a 1.7 times increased odds of reporting smoking reduction and 4.0 times increased odds of reporting reduced alcohol consumption. This demonstrates that having convenient methods of detecting pathogenic variants of the *SERPINA1* gene in commercial testing could benefit patients in the long run in terms of reducing risks of complications from AATD.<sup>26</sup>

Balcar, et al. (2022) studied the association between the alpha-1 antitrypsin Pi\*Z allele and liver disease. The study included 1118 patients with advanced chronic liver disease, all of whom had undergone genotyping for the Pi\*Z/Pi\*S allele. Compared to non-carriers, Pi\*Z carriers had more severe portal hypertension and hepatic dysfunction. “Harbouring the Pi\*Z allele was significantly associated with an increased probability of liver transplantation/liver-related death,” but “the Pi\*S allele was unrelated to liver disease severity” and “Pi\*S carriers had no increased risk of events.” The authors concluded that “genotyping for the Pi\*Z allele identifies patients with ACLD at increased risk of adverse liver-related outcomes, thereby improving prognostication.”<sup>27</sup>

Clark, et al. (2018) studied the clinical and histologic features of individuals with AATD. The study included 94 non-cirrhotic adults with Pi\*ZZ AATD. “The prevalence of clinically significant liver fibrosis ( $F \geq 2$ ) was 35.1%. Alanine aminotransferase, aspartate aminotransferase and gamma-glutamyltransferase values were higher in the  $F \geq 2$  group.” Metabolic syndrome, the presence of accumulated abnormal AAT in hepatocytes, portal inflammation, and hepatocellular degeneration were all associated with clinically significant fibrosis. The authors concluded that “over one-third of asymptomatic and lung affected adults with 'PI\*ZZ' AATD have significant underlying liver fibrosis” and that “liver disease in this genetic condition may be related to a "toxic gain of function" from accumulation of AAT in hepatocytes.”<sup>28</sup>

Eriksson, et al. (1986) studied the association between AATD and cirrhosis and primary liver cancer. The study included 17 autopsy cases of individuals with AATD. Each autopsy was matched with four control cases. “The results indicated a strong relation between alpha 1-antitrypsin deficiency and cirrhosis and primary liver cancer.”<sup>29</sup>

Fromme, et al. (2022) studied the association between AATD and hepatobiliary phenotypes. The study included 1104 participants (586 Pi\*ZZ, 239 Pi\*SZ, 279 non-carriers). “Pi\*ZZ individuals displayed the highest liver enzyme values, the highest occurrence of liver fibrosis/cirrhosis and primary liver cancer... Pi\*SZ participants displayed higher liver enzymes, more frequent liver fibrosis/cirrhosis... Subjects with Pi\*MZ genotype had slightly elevated liver enzymes and moderately increased odds for liver fibrosis/cirrhosis... Individuals with homozygous Pi\*S mutation (Pi\*SS genotype) harboured minimally elevated alanine aminotransferase values.” The authors concluded that their findings classify hepatobiliary phenotypes with their most relevant AATD genotypes.<sup>30</sup>

The Childhood Liver Disease Research Network Longitudinal Observational Study of Genetic Causes of Intrahepatic Cholestasis<sup>31</sup> is a longitudinal study about pediatric cholestatic liver disease. The study included 350 participants ages zero to 25 with native livers. Overall, 18 participants developed hypertension, and two died, but “there was no difference in participants with or without preceding neonatal cholestasis progressing to transplantation or death during the study, or in experiencing portal hypertension.” The authors concluded that, in youth with AATD, “progression to liver transplantation is slow and death is rare, but the risk of complications and severe liver disease progression persists throughout childhood.” The authors also note that “A history of neonatal cholestasis is a weak predictor of severe disease.”<sup>31</sup> Teckman, et al. (2023) then focused on neonatal cholestasis in children with AATD, using two subgroups: participants with neonatal cholestasis (n=46), and all participants who progressed to liver transplant (n=119). The authors reported “an association of neonatal gamma-glutamyl transpeptidase elevation to more severe disease, and a higher rate of neonatal cholestasis progression to portal hypertension than previously reported (41%) occurring at median age of 5 months.” All participants, regardless of neonatal cholestasis, were at risk of progression to liver transplant, but of the participants that progressed to liver transplant, those with neonatal cholestasis were significantly younger at transplant than those without neonatal cholestasis. The authors further concluded that “patients with AATD and neonatal cholestasis are at risk of early progression to severe liver disease, but the risk of severe disease extends throughout childhood.”<sup>32</sup>

Lin, et al. (2019) completed a systematic literature review of AATD deficiency-associated liver disease in children and put together diagnostic testing recommendations. The literature review revealed that “liver disease occurs in 10% of children, manifested by cholestasis, pruritus, poor feeding, hepatomegaly, and splenomegaly, but the presentation is highly variable.” The authors recommend genetic testing for AATD in children with

unexplained liver disease or suspected AATD, noting “consensus guidelines recommend diagnostic testing for all patients who have unexplained liver disease” (level of evidence for recommendations: A, based on consistent and good quality patient-oriented evidence).<sup>33</sup>

## Guidelines and Recommendations

### American Thoracic Society/European Respiratory Society (ATS/ERS)

The ATS/ERS released joint guidelines on the “Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency.” These recommendations are as follows:<sup>9</sup>

#### Policy Guidelines

Recommendations were classified as follows:

Type A: Genetic testing is recommended

Type B: Genetic testing should be discussed and could be accepted or declined

Type C: Genetic testing is not recommended, i.e., should not be encouraged

Type D: Recommend against genetic testing, i.e., should be discouraged

Type A recommendations for diagnostic testing in the following situations:

1. Symptomatic adults with emphysema, COPD or asthma with airflow obstruction that is not completely reversible with aggressive treatment with bronchodilators
2. Individuals with unexplained liver disease, including neonates, children, and adults, particularly the elderly
3. Asymptomatic individuals with persistent obstruction on pulmonary function tests with identifiable risk factors (e.g., cigarette smoking, occupational exposure)
4. Adults with necrotizing panniculitis
5. Siblings of an individual with known alpha-1 antitrypsin (AAT) deficiency

Type B recommendations for diagnostic testing in the following situations:

1. Adults with bronchiectasis without evidence etiology
2. Adolescents with persistent airflow obstruction
3. Asymptomatic individuals with persistent airflow obstruction and no risk factors
4. Adults with C-ANCA positive (anti-proteinase 3-positive) vasculitis
5. Individuals with a family history of COPD or liver disease not known to be attributed to AAT deficiency
6. Distant relatives of an individual who is homozygous for AAT deficiency
7. Offspring or parents of an individual with homozygous AAT deficiency
8. Siblings, offspring, parents or distant relatives of an individual who is heterozygous for AAT deficiency
9. Individuals at high risk of having AAT deficiency-related diseases
10. Individuals who are not at risk themselves of having AAT deficiency but who are partners of individuals who are homozygous or heterozygous for AAT deficiency

Type C recommendations for diagnostic testing in the following situations

1. Adults with asthma in whom airflow obstruction is completely reversible
2. Predispositional testing
3. Population screening of smokers with normal spirometry

Type D recommendations for diagnostic testing in the following situations:

1. Predispositional fetal testing
2. Population screening of either neonates, adolescents or adults\*

\* Population screening is not recommended currently. However, a possible exception (type B recommendation) may apply in countries satisfying all three of the following conditions: (1) the prevalence of AAT deficiency is high (about 1/1,500, or more); (2) smoking is prevalent; and (3) adequate counseling services are available.

The following features should prompt suspicion by physicians that their patient may be more likely to have AAT deficiency:

#### Clinical Factors

- Early-onset emphysema (age of 45 years or less)
- Emphysema in the absence of a recognized risk factor (smoking, occupational dust exposure, etc.)
- Emphysema with prominent basilar hyperlucency
- Otherwise unexplained liver disease
- Necrotizing panniculitis
- Anti-proteinase three-positive vasculitis (C-ANCA [anti-neutrophil cytoplasmic antibody]-positive vasculitis)
- Bronchiectasis without evident etiology

The ATS/ERS also made statements on serum testing for AATD. “Serum phenotyping by isoelectric focusing performed by a reliable laboratory is the accepted “gold standard” for diagnosing AAT deficiency”. The guidelines recommend “that all subjects with COPD or asthma characterized by incompletely reversible airflow obstruction should be tested once for quantitative AAT determination. Also, individuals with evidence of cirrhosis of the liver with no known etiology should be tested for candidate phenotypes (e.g., PI\*ZZ, PI\*MZ, PI\*Mmalton) and testing should be considered in individuals with the syndrome of Wegener's granulomatosis (antiproteinase-3 vasculitis).”<sup>9</sup>

The ATS/ERS states that “Regarding hepatic presentations of AAT deficiency later in childhood, during adolescence, and in adulthood, reports indicate that patients may present with hepatosplenomegaly, ascites, upper gastrointestinal bleeding resulting from esophageal varices, chronic hepatitis, cirrhosis, or hepatic failure. The presentation of AAT deficiency may appear similar to other chronic liver diseases, including autoimmune hepatitis, drug-induced hepatitis, chronic viral hepatitis, and Wilson's disease. The weight of these reports suggests that patients with any unexplained features of chronic liver disease should be evaluated for AAT deficiency.”<sup>9</sup>

#### **American College of Gastroenterology (ACG)**

The ACG notes that “defective production of the alpha-1 antitrypsin protein may result in both panacinar emphysema and chronic obstructive pulmonary disease, as well as progressive liver disease, liver cirrhosis, and hepatocellular carcinoma” and recommends the following for AATD:

- “Patients with persistently elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) should undergo screening for alpha-1 antitrypsin (A1AT) deficiency with alpha-1 anti-trypsin phenotype.”
- Evaluation of hepatocellular injury (defined by the guidelines as “disproportionate elevation of AST and ALT levels compared with alkaline phosphatase levels”) includes testing for A1AT deficiency.”<sup>34</sup>

#### **National Organization for Rare Disorders**

The NORD publishes information on multiple rare disorders that may otherwise lack national guidelines and recommendations. One such disorder is neonatal cholestasis, which refers to impaired flow of bile from the liver cells into the intestine of a newborn. While neonatal cholestasis may be caused by viruses, metabolic disease, or rare disease that affect or impair the function of the liver, it can also be caused by genetic disorders. “The incidence of neonatal cholestasis is estimated to be ~1:2500 live births worldwide, and 25% to 50% are now

known to be associated with changes (variants or mutations) in specific genes.”<sup>35</sup> These genetic disorders include “alpha-1-antitrypsin deficiency, PFIC and Alagille syndrome.”<sup>35</sup>

### **World Health Organization (WHO)**

The WHO released a memorandum on AATD regarding AATD’s association with conditions such as COPD and asthma. Their recommendation is as follows: “It is therefore recommended that all patients with COPD and adults and adolescents with asthma be screened once for AAT deficiency using a quantitative test. Those with abnormal results on screening should undergo PI typing.”<sup>36</sup>

### **European Respiratory Society (ERS)**

The ERS published updated guidelines which recommend:<sup>37</sup>

“The quantitative determination of AAT levels in blood is a crucial first test to identify AATD. Quantitative deficiency must be supported by qualitative tests to identify the genetic mutation(s) causing AATD.”

“Protein phenotyping by isoelectric focusing identifies variants where AAT is present in the sample including the rarer variants F, I and P *etc.*”

“Genotyping allows a rapid and precise identification/exclusion of S and Z alleles and other variants, where specific primers are available.”

“Gene sequencing remains necessary for those cases where a null variant or a deficient variant other than Z or S is suspected.”

“Testing of relatives of identified patients should be considered after appropriate counselling.”

“Genetic testing should be carried out only after informed consent is given and in accordance with the relevant guidelines and legislation.”

The ERS has also noted that “there is no evidence to support efficacy of AAT augmentation therapy in PiSZ, PiMZ or current smokers of any protein phenotype.”<sup>37</sup>

### **Alpha-1 Foundation**

The Alpha-1 Foundation sponsored a medical and scientific advisory committee of experts to examine all relevant, recent literature to provide concise recommendations for the diagnosis and management of individuals with AATD.<sup>38</sup>

- “For family testing after a proband is identified, AAT level testing alone is not recommended because it does not fully characterize disease risk from AATD.”
- “For diagnostic testing of symptomatic individuals, they recommend genotyping for at least the S and Z alleles. Advanced or confirmatory testing should include Pi-typing, AAT level testing, and/or expanded genotyping.”
- “All patients with COPD, unexplained chronic liver disease, necrotizing panniculitis, granulomatosis with polyangiitis, or unexplained bronchiectasis should be tested for AATD.”
- “Parents, siblings, and children, as well as extended family of individuals identified with an abnormal gene for AAT, should be provided genetic counseling and offered testing for AATD (see guideline document for special considerations about testing minors).”
- “Monitoring of trough AAT levels to document adequate AAT augmentation dosing is not recommended (strong recommendation, moderate quality evidence).”

The Foundation also noted the following (these statements were not labeled recommendations):

- “For primary diagnosis of AATD the most sensitive and specific method of diagnosis is direct identification of the Z allele by genotyping. By also including the S allele, genotyping for the S and Z allele is greater than 99% specific and sensitive.”

- “AAT levels are insufficient to identify at risk individuals because the AAT level changes with inflammation, pregnancy, and in children.”
- “The range of serum AAT levels among individuals with specific genotypes is sufficiently broad that there is overlap between different genotypes. Thus, serum AAT levels cannot discriminate between different genotypes and additional AAT testing is needed.”<sup>38</sup>

### **Global Initiative for Chronic Obstructive Lung Disease (GOLD)**

The GOLD guideline notes that “The most relevant (albeit rare) genetic risk factor for COPD identified to date are mutations in *SERPINA1* gene leading to  $\alpha$ -1 antitrypsin deficiency. A number of other genetic variables have also been associated with reduced lung function and risk of COPD, but their individual effect size is small.”<sup>12</sup>

### **Canadian Thoracic Society (CTS)**

The CTS released guidelines on genetic testing for AATD, which are as follows:

- “We suggest targeted testing for A1AT deficiency be considered in individuals with COPD diagnosed before 65 years of age or with a smoking history of <20 pack years. (Grade of recommendation: 2C)”
- “We suggest targeted testing for A1AT deficiency not be undertaken in individuals with bronchiectasis or asthma. (Grade of recommendation: 2C)”<sup>39</sup>

### **National Institute Health and Care Excellence (NICE)**

In 2019 NICE published a guideline discussing chronic obstructive pulmonary disease (COPD). In it, they note that measurement of serum alpha-1 antitrypsin has a role in identifying deficiencies if the condition is “early onset, [of] minimal smoking history, or [has] family history.”<sup>40</sup>

### **Government of British Columbia**

The British Columbia guidelines on the diagnosis and management of COPD state that, “testing for A1AT deficiency is expensive, low yield, often duplicated and may not alter management in a meaningful way. Therefore, refer patients with high pre-test probability to a specialist.”<sup>41</sup>

## **Applicable State and Federal Regulations**

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <http://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

### **Food and Drug Administration**

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

On November 17, 2017, the FDA approved Grifols’ *SERPINA1* Variant Detection System as a qualitative in vitro molecular diagnostic system used to detect variants in *SERPINA1* gene in genomic DNA isolated from human specimens.<sup>10</sup> On November 7, 2019, the FDA approved Grifols’ AlphaID™, a cheek swab that can screen patients with COPD for alpha-1 antitrypsin deficiency. It “utilizes an FDA-approved genotyping assay

to screen for the 14 most prevalently reported genetic mutations associated with Alpha-1, including the S, Z, F, I alleles, as well as rare and null alleles, helping detect patients who are at risk for this treatable condition.”<sup>42</sup>

On April 6, 2017 the FDA approved the 23andMe PGS Genetic Health Risk Report for Alpha-1 Antitrypsin Deficiency (AATD) which determines if a person has variants associated with a higher risk of developing AATD-associated lung or liver disease. This report is based on a qualitative genetic test for single nucleotide polymorphism detection of the PI\*Z (rs28929474) and PI\*S (rs17580) variants in the *SERPINA1* gene by using the 23andMe Personal Genome Service.<sup>43</sup>

### Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
82103	Alpha-1-antitrypsin; total
82104	Alpha-1-antitrypsin; phenotype
82542	Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen
83789	Mass spectrometry and tandem mass spectrometry (eg, MS, MS/MS, MALDI, MS-TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen

Current Procedural Terminology© American Medical Association. All Rights reserved.

*Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.*

### Evidence-based Scientific References

1. Stoller J. Extrapulmonary manifestations of alpha-1 antitrypsin deficiency. Updated February 17, 2025 <https://www.uptodate.com/contents/extrapulmonary-manifestations-of-alpha-1-antitrypsin-deficiency>
2. NORD. Alpha-1 Antitrypsin Deficiency. Updated March 21, 2024. <https://rarediseases.org/rare-diseases/alpha-1-antitrypsin-deficiency/>
3. Stoller JK, Aboussouan LS. A review of alpha-1-antitrypsin deficiency. *American journal of respiratory and critical care medicine*. Feb 1 2012;185(3):246-59. doi:10.1164/rccm.201108-1428CI
4. Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha-1-antitrypsin deficiency between 1968 and 2003. *Chest*. Sep 2005;128(3):1179-86. doi:10.1378/chest.128.3.1179
5. de Serres FJ, Blanco I, Fernandez-Bustillo E. PI S and PI Z alpha-1 antitrypsin deficiency worldwide. A review of existing genetic epidemiological data. *Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace*. Dec 2007;67(4):184-208. doi:10.4081/monaldi.2007.476
6. Stoller J. Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency. Updated October 4, 2024. <https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-natural-history-of-alpha-1-antitrypsin-deficiency>
7. de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. *Clinical genetics*. Nov 2003;64(5):382-97.
8. Belmonte I, Nunez A, Barrecheguren M, et al. Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory. *Int J Chron Obstruct Pulmon Dis*. 2020;15:2421-2431. doi:10.2147/COPD.S269641
9. ATS/ERS. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. *American journal of respiratory and critical care medicine*. Oct 1 2003;168(7):818-900. doi:10.1164/rccm.168.7.818

10. Grifols. FDA approval of genetic test for alpha-1 deficiency and EMA approval of fibrin sealant. <https://www.grifols.com/documents/3627767/3632483/np-20171117-en.pdf>
11. AlphaID. AlphaID. <https://www.alphaid.com/en/hcp/home>
12. GOLD. Global Strategy for Prevention, Diagnosis, and Management of COPD: 2024 Report. <https://goldcopd.org/2024-gold-report/>
13. Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in diagnosis of alpha-1-antitrypsin deficiency: a continuing problem. *Chest*. Oct 2005;128(4):1989-94. doi:10.1378/chest.128.4.1989
14. Barrecheguren M, Monteagudo M, Simonet P, et al. Diagnosis of alpha-1 antitrypsin deficiency: a population-based study. *Int J Chron Obstruct Pulmon Dis*. 2016;11:999-1004. doi:10.2147/copd.s108505
15. Snyder MR, Katzmann JA, Butz ML, et al. Diagnosis of alpha-1-antitrypsin deficiency: An algorithm of quantification, genotyping, and phenotyping. *Clinical chemistry*. Dec 2006;52(12):2236-42. doi:10.1373/clinchem.2006.072991
16. Sorroche PB, Fernandez Acquier M, Lopez Jove O, et al. Alpha-1 Antitrypsin Deficiency in COPD Patients: A Cross-Sectional Study. *Archivos de bronconeumologia*. Nov 2015;51(11):539-43. doi:10.1016/j.arbres.2015.01.008
17. Corda L, Medicina D, La Piana GE, et al. Population genetic screening for alpha-1-antitrypsin deficiency in a high-prevalence area. *Respiration; international review of thoracic diseases*. 2011;82(5):418-25. doi:10.1159/000325067
18. Soriano JB, Lucas SJ, Jones R, et al. Trends of testing for and diagnosis of alpha-1-antitrypsin deficiency in the UK: more testing is needed. *The European respiratory journal*. Jul 2018;52(1)doi:10.1183/13993003.00360-2018
19. Greulich T, Nell C, Herr C, et al. Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015. *Orphanet journal of rare diseases*. Jun 10 2016;11(1):75. doi:10.1186/s13023-016-0453-8
20. Mattman A, Gilfix BM, Chen SX, et al. Alpha-1-antitrypsin molecular testing in Canada: A seven year, multi-centre comparison. *Clin Biochem*. Jul 2020;81:27-33. doi:10.1016/j.clinbiochem.2020.05.001
21. Hamesch K, Mandorfer M, Pereira VM, et al. Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi\*ZZ Mutation. *Gastroenterology*. Sep 2019;157(3):705-719.e18. doi:10.1053/j.gastro.2019.05.013
22. Strnad P, Buch S, Hamesch K, et al. Heterozygous carriage of the alpha-1-antitrypsin Pi\*Z variant increases the risk to develop liver cirrhosis. *Gut*. Jun 2019;68(6):1099-1107. doi:10.1136/gutjnl-2018-316228
23. Carreto L, Morrison M, Donovan J, et al. Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis. *Thorax*. Jul 2020;75(7):592-593. doi:10.1136/thoraxjnl-2019-214195
24. Murray JD, Willrich MA, Krowka MJ, et al. Liquid Chromatography-Tandem Mass Spectrometry-Based alpha-1-Antitrypsin (AAT) Testing. *Am J Clin Pathol*. Mar 15 2021;155(4):547-552. doi:10.1093/ajcp/aqaa149
25. Bellemare J, Gaudreault N, Valette K, et al. The Clinical Utility of Determining the Allelic Background of Mutations Causing Alpha-1 Antitrypsin Deficiency: The Case with the Null Variant Q0(Mattawa)/Q0(Ourém). *Chronic Obstr Pulm Dis*. Jan 2021;8(1):31-40. doi:10.15326/jcopdf.8.1.2020.0168
26. Ashenhurst JR, Nhan H, Shelton JF, et al. Prevalence of Alpha-1 Antitrypsin Deficiency, Self-Reported Behavior Change, and Health Care Engagement Among Direct-to-Consumer Recipients of a Personalized Genetic Risk Report. *Chest*. Feb 2022;161(2):373-381. doi:10.1016/j.chest.2021.09.041
27. Balcar L, Scheiner B, Urheu M, et al. Alpha-1 antitrypsin Pi\*Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease. *JHEP Rep*. Nov 2022;4(11):100562. doi:10.1016/j.jhepr.2022.100562
28. Clark VC, Marek G, Liu C, et al. Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort. *J Hepatol*. Dec 2018;69(6):1357-1364. doi:10.1016/j.jhep.2018.08.005
29. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha-1-antitrypsin deficiency. *N Engl J Med*. Mar 20 1986;314(12):736-9. doi:10.1056/nejm198603203141202
30. Fromme M, Schneider CV, Pereira V, et al. Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. *Gut*. Feb 2022;71(2):415-423. doi:10.1136/gutjnl-2020-323729

31. Teckman J, Rosenthal P, Hawthorne K, et al. Longitudinal Outcomes in Young Patients with Alpha-1-Antitrypsin Deficiency with Native Liver Reveal that Neonatal Cholestasis is a Poor Predictor of Future Portal Hypertension. *J Pediatr*. Dec 2020;227:81-86.e4. doi:10.1016/j.jpeds.2020.07.031
32. Teckman J, Rosenthal P, Ignacio RV, et al. Neonatal cholestasis in children with Alpha-1-AT deficiency is a risk for earlier severe liver disease with male predominance. *Hepatol Commun*. Dec 1 2023;7(12)doi:10.1097/hc9.0000000000000345
33. Lin HC, Kasi N, Quiros JA. Alpha1-Antitrypsin Deficiency: Transition of Care for the Child With AAT Deficiency into Adulthood. *Curr Pediatr Rev*. 2019;15(1):53-61. doi:10.2174/1573396314666181113094517
34. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. *The American journal of gastroenterology*. Jan 2017;112(1):18-35. doi:10.1038/ajg.2016.517
35. NORD. Neonatal Cholestasis. Updated January 25, 2024. <https://rarediseases.org/rare-diseases/idiopathic-neonatal-hepatitis/>
36. WHO. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. *Bull World Health Organ*. 1997;75(5):397-415.
37. Miravittles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. *The European respiratory journal*. Nov 2017;50(5)doi:10.1183/13993003.00610-2017
38. Sandhaus RA, Turino G, Brantly ML, et al. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. *Chronic Obstr Pulm Dis*. Jun 6 2016;3(3):668-682. doi:10.15326/jcopdf.3.3.2015.0182
39. Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. *Canadian respiratory journal*. Mar-Apr 2012;19(2):109-16. doi:10.1155/2012/920918
40. NICE. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Updated July 26, 2019. <https://www.nice.org.uk/guidance/ng115/chapter/Recommendations>
41. BC Guidelines. Chronic Obstructive Pulmonary Disease (COPD): Diagnosis and Management. Updated January 17, 2025. <https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/copd>
42. Grifols. Grifols introduces AlphaID™, a free cheek swab to screen for Alpha-1, the most common genetic form of COPD. Updated November 7. Accessed April 11, 2021. <https://www.grifols.com/en/view-news/-/news/grifols-introduces-alpha1-a-free-cheek-swab-to-screen-for-alpha-1-the-most-common-genetic-form-of-copd>
43. FDA. Decision Summary for 23andMe PGS Genetic Health Risk Report. U.S. Food and Drug Administration. [https://www.accessdata.fda.gov/cdrh\\_docs/reviews/DEN160026.pdf](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN160026.pdf)

## Revision History

Effective Date	Summary
02/01/2026	Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references. Literature review did not necessitate any modifications to coverage criteria.

01/01/2025	<p>Reviewed and Updated: Updated background, guidelines, and evidence-based scientific references. Literature review necessitated the following changes in coverage criteria:</p> <p>Addition of “once per lifetime” to CC1. Now reads: “1) For individuals who are suspected of having alpha-1 antitrypsin (AAT) deficiency, serum quantification of alpha-1 antitrypsin (AAT) protein and AAT phenotyping or AAT proteotyping (see Note 1) MEETS COVERAGE CRITERIA once per lifetime in any of the following situations:”</p> <p>Edited CC1.b. to include examples of unexplained liver disease. Now reads: “b) For individuals with unexplained liver disease (e.g., chronic hepatitis with or without cirrhosis, chronically elevated aminotransferase levels, portal hypertension, primary liver cancer).”</p> <p>New CC1h: “h) For individuals with neonatal cholestasis.”</p>
11/03/2023	<p>Initial presentation of RTM only version.</p> <p>Compared to the comprehensive version, remove “or genetic testing for AAT deficiency” from CC1.</p> <p>Compared to the comprehensive version, CC3 and CC4 deleted.</p> <p>Compared to the comprehensive version, remove “Initial genetic testing should be restricted to genotyping of SERPINA1 S and Z allele mutations.”</p> <p>Compared to the comprehensive version, removed Note 2.</p>
12/01/2022	<p>Reviewed and Updated: Updated background, guidelines, and evidence-based scientific references. Literature review did not necessitate any modification to the coverage criteria. Coverage criteria edited for clarity:</p> <p>CC2 now reads: “In individuals with negative genotype testing for common variants or discordant results between A1AT serum levels and proteotype, isoelectric focusing/phenotyping MEETS COVERAGE CRITERIA when there is strong suspicion of the disease based on laboratory testing and symptoms.”</p> <p>CC4 now reads: “Genetic testing for alpha-1 antitrypsin deficiency MEETS COVERAGE CRITERIA for at risk individuals with a first-degree relative with AAT deficiency.”</p> <p>CC5 now reads :“When there is strong suspicion of the disease based on laboratory testing and symptoms in an individual with negative genotype testing for common variants or discordant results between A1AT serum levels and proteotype or phenotype, full SERPINA1 gene sequencing MEETS COVERAGE CRITERIA.”</p>
06/01/2022	Initial Policy Implementation

**Medicaid Business Segment:**

**Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.**

**LINE OF BUSINESS:**

**Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD’s and NCD’s will supercede this policy. For PA Medicaid Business segment, this policy applies as written.**

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.